Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Tumor-targeted degradation of SIRPα reprograms tumor-associated macrophages and restores antitumor immunity

ABSTRACT: Therapies targeting the CD47–SIRPα "don't eat me" axis are currently hampered by limited tissue penetration and dose-limiting hematotoxicity. Here, we report a tumor-targeted mRNA nanotherapeutic that selectively degrades SIRPα on macrophages to unleash antitumor immunity in colorectal cancer. We formulated mRNA encoding an Fc-fused SIRPα degrader into VEGFR2-targeted lipid nanoparticles (LNPs) to achieve tumor-specific delivery. This system triggers lysosomal degradation of SIRPα, repolarizing tumor-associated macrophages toward a pro-inflammatory, phagocytic state that drives CD8⁺ T cell priming. In contrast to the hematologic toxicity associated with systemic CD47 blockade, this strategy demonstrated superior tumor control in syngeneic and orthotopic CRC models while preserving a normal hematologic profile. Single-cell transcriptomics confirmed the remodeling of the immunosuppressive myeloid landscape. These findings establish targeted SIRPα degradation as a potent, safe alternative to systemic CD47 blockade, offering a versatile platform to reprogram myeloid checkpoints in solid tumors.

ORGANISM(S): Mus musculus

PROVIDER: GSE331406 | GEO | 2026/05/26

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

N-terminal pyroglutamate in CD47 is involved in SIRPα interactions

Project description:T-cell immune checkpoint inhibitors have revolutionized cancer immunotherapy. In addition to T cells, immune checkpoint molecules have also been described for myeloid cells, with CD47 on tumor cells and Signal Regulatory Protein α (SIRPα) on effector cells being the most established example (Maute et al. Immunooncol Technol. 2022). Blockade of this checkpoint by CD47 or SIRPα targeting molecules has been demonstrated to enhance the efficacy of therapeutic antibodies in many preclinical tumor models (Müller et al. Blood. 2022, Schewe et al. Hemasphere. 2024). Next to CD47/SIRPα blocking molecules, inhibition of Glutaminyl-Peptide Cyclotransferase-Like (QPCTL) - the enzyme that catalyzes functionally relevant pyroglutamate (pGlu) formation on many peptides and proteins including CD47 - was shown to modify the myeloid tumor cell infiltrate (Barreira et al. Nat Immunol. 2022) and to improve antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC) against tumor cells (Logtenberg et al. Nat Med. 2019, Wu et al. Cell Res. 2019, Baumann et al. Front Immunol. 2021). Crystallographic analyses of CD47 in complex with SIRPα revealed that the CD47 binding pocket for SIRPα contains pGlu at the N-terminus (Hatherley et al. Mol Cell. 2008). However, on cellular level the direct involvement of pGlu in the CD47/SIRPα interaction has not been confirmed yet. We generated human CD47 Fc proteins, that contain either a native CD47 ectodomain with N-terminal pGlu (CD47-wt) or a mutated version with alanine at the N-terminus (CD47-Q1A), which was confirmed by mass spectrometry. Differential binding of CD47-wt and CD47-Q1A revealed that pGlu on CD47 is essential for binding to SIRPα on macrophages, supporting that inhibition of QPCTL is a good therapeutic option for enhanced tumor cell killing through CD47/SIRPα interference.

2026-05-19 | PXD066444 | Pride

Tumor cell intrinsic type I interferon signaling dictates CD47-SIRPα blockade immunotherapy via metabolic reprograming [dataset 2]

Project description:Type I interferons (IFN-Is) have been well recognized for their roles in immune cells in tumor immunotherapy. However, their direct effects on tumor cells are less understood. Oxidative phosphorylation (OXPHOS) is typically latent in tumor cells. However, whether OXPHOS can be targeted for immunotherapy remains unclear. Here, we found that tumor cell responsiveness to IFN-Is is essential for CD47-SIRPα blockade immunotherapy. Interestingly, IFN-Is directly reprogram tumor cell metabolism by activating OXPHOS for ATP production via ISG15. ATP extracellular release is also enhanced by IFN-Is via autophagy. Tumor cells with a genetic deficiency in OXPHOS or autophagy were resistant to CD47-SIRPα blockade. ATP released upon CD47-SIRPα blockade primes the anti-tumor T cell response via ATP-P2X7 receptor-mediated dendritic cell activation. Further combination with inhibitors of ATP-degrading ectoenzymes, CD39 and CD73, showed synergistic anti-tumor effects. Together, these data reveal the unrecognized mechanisms of IFN-Is on tumor cell metabolic reprograming in tumor immunotherapy and provide novel strategies harnessing this pathway for enhanced efficacy of CD47-SIRPα blockade.

2024-06-04 | GSE235112 | GEO

Tumor cell intrinsic type I interferon signaling dictates CD47-SIRPα blockade immunotherapy via metabolic reprograming [dataset 1]

Project description:Innate immune checkpoint has emerging as a highly potential target for cancer immunotherapy in recent years. The CD47-SIRPα axis is the best-studied innate checkpoint in cancer. However, the transcription profile of tumor cell duiring CD47-SIRPα blockade therapy remains unclear.

2024-06-04 | GSE235111 | GEO

CD47-SIRPα axis blockade in NASH promotes necroptotic hepatocyte clearance by liver macrophages and decreases hepatic fibrosis

Project description:Necroptosis contributes to hepatocyte death (HC) in non-alcoholic steatohepatitis (NASH), but the fate and roles of necroptotic hepatocytes (necHCs) in NASH remain unknown. We show here that the accumulation of necHCs is associated with worsening NASH in humans and in mice with diet-induced NASH and that NASH liver showed evidence of impaired necHC clearance by liver macrophages. Further, the "don't-eat-me" ligand CD47 on HCs and its receptor, SIRPα, on liver macrophages, were markedly upregulated in human and mouse NASH. In vitro, anti-CD47 or anti-SIRPα promoted necHC engulfment by primary liver macrophages. In a proof-of-concept mouse model of inducible HC necroptosis, anti-CD47 increased necHC uptake by liver macrophages and inhibited hepatic stellate cell (HSC) activation, which is responsible for liver fibrogenesis. Most importantly, treatment of two mouse models of diet-induced NASH with anti-CD47 or anti-SIRPα increased the uptake of necHC by liver macrophages and decreased HSC activation and liver fibrosis. These findings provide evidence that impaired clearance of necHCs by liver macrophages due to CD47-SIRPα upregulation contributes to fibrotic NASH and suggest therapeutic blockade of the CD47-SIRPα axis as a strategy to decrease the accumulation of necHCs in NASH liver and dampen the progression of hepatic fibrosis.

2022-11-25 | GSE197111 | GEO

SIRPα-CD47 axis regulates ILC2 effector function and alleviates airway hyperreactivity via modulating energy metabolism.

Project description:Type-2 innate lymphoid cells (ILC2) are part of a growing family of innate lymphocytes known for their crucial role in both the development and exacerbation of allergic asthma. In this study, we aim to elucidate the critical role of the suppressor molecule signal regulatory protein alpha (SIRPα), which interacts with CD47, in controlling ILC2-mediated airway hyperreactivity (AHR). Our data indicate that activated ILC2s upregulate the expression of SIRPα, and the interaction between SIRPα and CD47 effectively suppresses both ILC2 proliferation and effector function. To evaluate the efficacy of SIRPα in regulating ILC2-mediated AHR, we utilized SIRPα and CD47 deficient mice in a murine model of allergen-induced AHR. Our findings suggest that the absence of SIRPα leads to the overactivation of ILC2s. Conversely, engagement with SIRPα reduces ILC2 cytokine production and effectively regulates ILC2-dependent AHR. Furthermore, the SIRPα-CD47 axis modulates mitochondrial metabolism through the JAK/STAT and ERK/MAPK signaling pathways, thereby regulating NF-κB activity and the production of type two cytokines. Additionally, our studies on human cells have revealed that SIRPα is inducible and expressed on human ILC2s, and administration of a SIRPα agonist effectively suppresses the effector function and cytokine production of ILC2s. Moreover, administering human CD47-Fc to humanized ILC2 mice effectively alleviated AHR and lung inflammation. These findings highlight the promising therapeutic potential of targeting the SIRPα-CD47 axis in the treatment of ILC2-dependent allergic asthma.

2024-08-10 | GSE264061 | GEO

Macrophage PAK2 controls the SIRPα immune checkpoint via cytoskeletal dynamics and endocytic trafficking

Project description:Professional phagocytes are essential for immunomodulation, antimicrobial control, and initiation and resolution of inflammation. These cells rely on dynamic cytoskeletal rearrangements to respond to their environment. This plasticity requires a network of positive and negative regulators to control biomechanics and signaling circuits. P21-activated kinases (PAKs) regulate the actomyosin cytoskeleton, cell proliferation, and gene expression, yet their contributions to phagocyte functions remain unresolved. Analyzing PAK1/2-deficient phagocytes and utilizing a PAK inhibitor we show that PAK2 governs physio-mechanical macrophage properties, leading to membrane expansion, hyperphagic behavior and disruption of endocytic transport when absent, while PAKs cooperate to restrain oxidative neutrophil responses. In PAK1/mPAK2 ablated mice cytoskeletal remodeling combined with low-grade chronic inflammation prompts the spontaneous development of a macrophage-driven hematologic malignancy. Macrophage PAK2 ablation or inhibition markedly enhances cancer cell uptake by exerting biophysical control over the CD47-SIRPα checkpoint, indicating that biomechanical modification of macrophages holds promise in cancer immunotherapy.

2025-10-31 | PXD062325 | Pride

Effects of a humanized CD47 antibody and SIRPα on triple negative breast carcinoma stem cells

Project description:Signal regulatory protein alpha (SIRPα, designated CD172a), also called SHPS-1 (SHP substrate 1) binds to CD47, a receptor for Thromobospondin-1 (TSP1). To block CD47-SIRP interaction, several CD47 blocking agents are in clinical trials. The purpose of this project is to explore the effects of SIRPFc signaling on bCSCs (breast cancer stem cells) derived from MDA-MB- 231 cells, when bCSCs were treated with either SIRPFc or CD47 blocking antibody CC90002 from Celgene Corporation.

2024-02-20 | GSE247052 | GEO

Tumor cell intrinsic type I interferon signaling dictates CD47-SIRPα blockade immunotherapy via metabolic reprograming.

Project description:Tumor cell intrinsic type I interferon signaling dictates CD47-SIRPα blockade immunotherapy via metabolic reprograming.

| PRJNA984607 | ENA

Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor associated macrophages to improve therapeutic outcomes in solid tumors

Project description:CD47/SIRPα and CD24/Siglec-10 signaling pathways have been found to suppress macrophage phagocytosis of malignant cells. We constructed a recombinant oncolytic adenovirus expressing a fusion protein composed of the extracellular domains of murine SIRPα and Siglec-10 (SIRPα/Siglec-10), termed AdV-mSS. Intratumoral administration of AdV-SS markedly enhanced antitumor efficacy than AdV-Ctrl in multiple solid tumor models. To reveal differences in biological processes between them. subcutaneous 14-day H22-CAR -bearing BALB/c mice were intratumorally injected with PBS, 5 × 10^8 IFU AdV-Ctrl, or 5 × 10^8 IFU AdV-mSS twice. Forty-eight hours post-treatment, we harvested tumor tissue and sorted these TAMs by anti-mouse F4/80 magnetic beads. Samples were subjected to transcriptome sequencing.

2025-04-09 | GSE275905 | GEO

The SIRPα-CD47 immune checkpoint in NK cells

Project description:The SIRPα-CD47 immune checkpoint in NK cells

| PRJEB36016 | ENA